HIND NASDAQ
Vyome Holdings, Inc.
1W: -8.7%
1M: -5.2%
3M: -9.5%
YTD: -43.7%
1Y: -81.7%
3Y: -100.0%
5Y: -100.0%
$1.99
-0.01 (-0.50%)
Weekly Expected Move ±6.2%
$2
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$14.0M
52W Range1.75-18.6
Volume10,057
Avg Volume25,841
Beta1.50
Dividend—
Analyst Ratings
Company Info
CEOVenkateswarlu Nelabhotla
Employees18
SectorHealthcare
IndustryBiotechnology
IPO Date2016-10-06
Websitevyometx.com
100, Overlook Center
Cambridge, MA 02138
US
Cambridge, MA 02138
US
973 832 8147
About Vyome Holdings, Inc.
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Latest News
12 Health Care Stocks Moving In Thursday's After-Market Session
Vyome Holdings, Inc. reports FY results
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Pomichter Stanley D | A-Award | 17,833 | $0.66 | 2025-11-13 |
| Tincoff John M. III | A-Award | 17,833 | $0.66 | 2025-11-13 |
| Sengupta Shiladitya | A-Award | 624,432 | $0.66 | 2025-11-13 |
| Nelabhotla Venkatesw | A-Award | 615,149 | $0.66 | 2025-11-13 |
| Pomichter Stanley D | 0 | — | 2025-08-15 |